Sheaff Brock Investment Advisors LLC raised its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 81.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 3,000 shares of the biotechnology company’s stock after buying an additional 1,350 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Sarepta Therapeutics were worth $226,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in the business. Amundi Pioneer Asset Management Inc. grew its stake in shares of Sarepta Therapeutics by 32.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology company’s stock worth $18,428,000 after acquiring an additional 38,194 shares during the period. EFG Asset Management Americas Corp. grew its position in Sarepta Therapeutics by 24.0% during the second quarter. EFG Asset Management Americas Corp. now owns 18,732 shares of the biotechnology company’s stock valued at $2,846,000 after buying an additional 3,631 shares during the period. Harbour Capital Advisors LLC grew its position in Sarepta Therapeutics by 32.3% during the second quarter. Harbour Capital Advisors LLC now owns 10,580 shares of the biotechnology company’s stock valued at $1,608,000 after buying an additional 2,582 shares during the period. Evolution Wealth Advisors LLC bought a new stake in Sarepta Therapeutics during the second quarter valued at approximately $25,000. Finally, Nisa Investment Advisors LLC grew its position in Sarepta Therapeutics by 10.4% during the second quarter. Nisa Investment Advisors LLC now owns 1,325 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 125 shares during the period. 95.06% of the stock is owned by institutional investors and hedge funds.
In related news, CEO Douglas S. Ingram bought 16,252 shares of the stock in a transaction dated Monday, August 12th. The shares were purchased at an average price of $123.07 per share, with a total value of $2,000,133.64. Following the completion of the acquisition, the chief executive officer now owns 424,405 shares of the company’s stock, valued at $52,231,523.35. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard Barry bought 1,300 shares of the stock in a transaction dated Monday, August 12th. The stock was bought at an average cost of $122.50 per share, for a total transaction of $159,250.00. Following the acquisition, the director now directly owns 3,173,365 shares of the company’s stock, valued at approximately $388,737,212.50. The disclosure for this purchase can be found here. Insiders bought 35,752 shares of company stock worth $3,940,114 in the last three months. Insiders own 6.60% of the company’s stock.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) EPS for the quarter, missing the consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. The company had revenue of $94.67 million during the quarter, compared to analysts’ expectations of $91.05 million. During the same period last year, the firm posted ($1.67) EPS. Sarepta Therapeutics’s quarterly revenue was up 28.8% compared to the same quarter last year. On average, equities research analysts expect that Sarepta Therapeutics Inc will post -4.94 earnings per share for the current year.
Several analysts recently issued reports on SRPT shares. Bank of America cut their target price on shares of Sarepta Therapeutics from $200.00 to $189.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. HC Wainwright set a $160.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Friday, September 13th. BidaskClub upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, October 4th. Morgan Stanley cut their target price on shares of Sarepta Therapeutics from $220.00 to $160.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, Credit Suisse Group lowered their price target on shares of Sarepta Therapeutics from $207.00 to $201.00 and set an “outperform” rating on the stock in a report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Buy” and an average price target of $189.00.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Article: Why is insider trading harmful?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.